Cardiol Therapeutics Business Summary

Cardiol Therapeutics Inc. (CRDL) is a clinical-stage life sciences company focused on the research and development of anti-inflammatory and anti-fibrotic therapies for cardiovascular disease. The company operates as a pure-play drug discovery entity, generating value through the clinical advancement of its lead small-molecule candidate, CardiolRx™, a pharmaceutically manufactured oral cannabidiol solution. Its primary business segments are centered on three late-stage clinical programs: the MAVERIC Phase III trial for recurrent pericarditis, the ARCHER program for acute myocarditis, and the development of CRD-38, a subcutaneous formulation targeting heart failure. As of March 2026, Cardiol remains pre-revenue, with a business model predicated on achieving regulatory milestones to facilitate future commercialization, licensing, or strategic partnerships. Within the competitive landscape, Cardiol contends with Ventyx Biosciences, Tenaya Therapeutics, BioCardia, and Milestone Pharmaceuticals, positioning itself as a specialized leader in modulating inflammasome pathway activation for rare cardiac conditions with Orphan Drug Designations. Cardiol was founded in 2017 by a team of veteran life sciences executives, including President and CEO David Elsley, who previously founded Vasogen Inc. and grew it to a $1 billion market capitalization. The leadership team is characterized by deep industry pedigree; CFO Chris Waddick brings over 30 years of experience from Vasogen and the energy sector, while Chief Medical Officer Dr. Andrew Hamer previously served as Executive Director at Amgen, where he led global development for the blockbuster drug Repatha®. The company’s strategic direction is overseen by Chairman Dr. Guillermo Torre-Amione, a renowned cardiologist and President of TecSalud, and a board that includes Dr. Timothy J. Garnett, the former Chief Medical Officer of Eli Lilly. Notable institutional backing was reinforced in early 2026 through a $14.85 million bought deal financing, supporting the company's clinical trajectory into late 2026.